EQUITY RESEARCH MEMO

Van Hoef Consulting

Generated 5/10/2026

Executive Summary

Conviction (model self-assessment)65/100

Van Hoef Consulting is a specialized Swiss consulting firm delivering medical and scientific expertise to the biopharma and biotech sectors, with a strong focus on oncology, hematology, and hematopoietic cell transplantation. Founded in 2010 and based in Zurich, the company provides services across clinical development, medical affairs, and regulatory strategy, catering to companies of all sizes. By leveraging deep domain knowledge, Van Hoef Consulting helps clients improve disease outcomes and navigate complex regulatory pathways. The firm's boutique approach and specialization in high-value therapeutic areas position it as a trusted partner for innovative biotechnology and pharmaceutical companies seeking expert guidance in drug development and market access.

Upcoming Catalysts (preview)

  • Q3 2026Announcement of new major client contract in cell therapy70% success
  • Q4 2026Expansion of service offerings into gene therapy consulting50% success
  • Q2 2026Key hire of senior regulatory strategist with FDA/EMA experience60% success
Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)